Guide
How to Select Antibodies and Antigens for Lateral Flow Assay Development
Learn how to select antibodies and antigens for lateral flow assay development, including affinity, antibody pairing, specificity, conjugation and matrix compatibility.
Antibodies and antigens are central to the analytical performance of a lateral flow immunoassay (LFIA). However, selecting a reagent for LFIA development involves more than choosing the antibody with the highest reported affinity or the antigen with the highest purity.
In a lateral flow system, binding takes place while samples and reagents migrate through a porous membrane. Antibody pairing, epitope accessibility, conjugation behavior, membrane interaction and sample matrix can therefore influence the final result.[1–4]
1
Start with assay format
Define the target analyte and whether the assay will use a sandwich, antibody-detection or competitive format.
2
Evaluate the pair
For sandwich assays, capture and detection antibodies should be assessed as a functional pair rather than individually.
3
Validate on the strip
ELISA or kinetic measurements are useful screening tools, but final suitability should be confirmed in the intended LFIA format.
1. Define the Target and Assay Format First
Raw-material selection should begin with the biological target and the intended assay architecture. Different LFIA formats require antibodies and antigens to perform different functions.
| Assay Format | Typical Application | Key Reagent Requirement |
|---|---|---|
| Sandwich assay | Proteins, biomarkers and pathogen antigens | Compatible capture and detection antibodies capable of binding the target simultaneously. |
| Antibody-detection assay | Detection of target-specific antibodies | An antigen that presents relevant antibody-recognition epitopes under the assay conditions. |
| Competitive assay | Small molecules and haptens | Specific antibodies together with an appropriate antigen or analyte conjugate. |
This distinction is important because a reagent that is suitable for one immunoassay architecture may not automatically be appropriate for another.[1,3]
2. What Should Be Considered When Selecting an Antigen?
Antigen selection is especially important when recombinant proteins are used for antibody generation, antibody screening or antibody-detection assays.
Biological relevance
The antigen should represent the intended analytical target as closely as practical. Depending on the application, developers may need to consider target abundance, sequence conservation, structural accessibility and the molecular form present in the real sample.[3]
Epitope integrity
Recombinant expression and purification can influence protein folding and structural presentation. This can be relevant when an antibody recognizes a conformational rather than a simple linear epitope.
For this reason, strong binding to a recombinant screening antigen does not by itself guarantee equivalent recognition of the native analytical target.
Consistency
Purity is important, but it is not the only useful specification. Identity, concentration, structural integrity, storage stability and lot-to-lot consistency should also be considered when selecting an antigen for continued assay development.
Practical point
Antigen selection should be driven by the intended diagnostic target rather than simply by recombinant-protein availability.
3. Select Antibodies as Functional Pairs
In a sandwich LFIA, one antibody is generally immobilized at the test line while another is associated with a detection label such as colloidal gold or latex particles.
Both antibodies must recognize accessible and compatible regions of the target. If their epitopes overlap or sterically interfere with one another, formation of an efficient sandwich complex can be reduced.[2,3]
This means that individual antibody performance is not enough to predict pair performance.
Why pair screening matters
A published SARS-CoV-2 LFIA development study screened 1,021 capture/detection antibody combinations directly in the lateral-flow format. The authors reported that results obtained in other assay formats did not always predict LFIA performance because flow, immobilization and reaction kinetics are different on nitrocellulose.[5]
Epitope mapping or epitope-binning data can help reduce the number of candidate combinations, but practical pair screening remains valuable during assay development.
4. Affinity Matters — but It Is Not the Only Selection Criterion
Antibody affinity describes the strength of the antibody–antigen interaction. Binding kinetics, including association and dissociation behavior, can also be relevant because LFIA reactions occur while analytes and reagents move through the membrane.[2,3]
Techniques such as surface plasmon resonance (SPR) and bio-layer interferometry (BLI) can provide useful kinetic information during candidate characterization.
However, the antibody with the lowest reported equilibrium dissociation constant (KD) should not automatically be assumed to be the best LFIA reagent.
Final performance may also depend on:
| Parameter | Why It Matters in LFIA |
|---|---|
| Specificity | Helps reduce recognition of related or non-target molecules. |
| Epitope accessibility | The target region must remain accessible under actual assay conditions. |
| Pair compatibility | Capture and detector antibodies must form an effective sandwich complex. |
| Conjugation behavior | Labeling can alter antibody orientation, accessibility or functional activity. |
| Matrix compatibility | Whole blood, serum, plasma, saliva and other matrices can affect binding and flow differently. |
5. Check Performance After Conjugation
Detection antibodies are commonly associated with labels such as gold nanoparticles, latex particles or fluorescent particles. The conjugation method therefore becomes part of the assay system rather than a separate manufacturing step.[4]
Conjugation conditions can influence particle stability, antibody accessibility and the biological activity of the final conjugate.
An antibody that performs well as a free molecule may therefore behave differently after it is adsorbed or chemically coupled to a particle.
Recommended evaluation
Compare candidate detection antibodies after conjugation and monitor positive signal, background, particle stability and release from the conjugate pad.
6. Test the Intended Sample Matrix Early
Biological samples are complex. Differences in protein content, viscosity, pH, ionic strength and other matrix components can influence both immunochemical reactions and capillary flow.
The sample pad and running buffer can reduce some matrix effects, but development performed only in purified buffer may not accurately represent performance in the intended specimen.[1]
Candidate antibodies and antigens should therefore be challenged with the actual or representative sample matrix as development progresses.
7. A Practical LFIA Raw-Material Screening Workflow
A structured screening strategy helps developers avoid optimizing an assay around an unsuitable reagent pair.
Define the analytical target
Determine what molecular species the assay needs to detect and in which sample type.
Select the assay architecture
Decide whether a sandwich, antibody-detection or competitive format is most appropriate.
Characterize candidate reagents
Review specificity, antigen recognition and, where useful, affinity or kinetic data.
Screen capture and detector combinations
Evaluate multiple orientations rather than assuming two compatible antibodies are interchangeable.
Evaluate the labeled reagent
Confirm performance after conjugation to the selected reporter particle.
Move screening onto the strip
Test candidates under representative membrane, buffer and flow conditions.
Challenge the intended matrix
Compare positive signal, background, specificity and reproducibility using representative samples.
Key Takeaway
Selecting antibodies and antigens for lateral flow development is a system-level decision.
Affinity and purity are useful starting parameters, but they cannot independently predict final LFIA performance. Assay architecture, antibody pairing, epitope accessibility, conjugation, membrane behavior and sample matrix should be evaluated together.
For this reason, the most reliable raw-material selection process combines biochemical characterization with functional screening under conditions that progressively resemble the final lateral flow assay.
Developing a Lateral Flow Assay?
EXIMIO provides antibodies, antigens and practical technical support for lateral flow assay development, from raw-material selection and antibody pair screening to assay optimization and scale-up.
References
- Koczula KM, Gallotta A. Lateral flow assays. Essays in Biochemistry. 2016;60(1):111–120. DOI: 10.1042/EBC20150012. PMID: 27365041.
- Sukumaran A, Thomas T, Thomas R, et al. Development and Troubleshooting in Lateral Flow Immunochromatography Assays. Indian Journal of Clinical Biochemistry. 2021;36(2):208–212. DOI: 10.1007/s12291-020-00887-5. PMID: 33867712.
- Calidonio JM, Hamad-Schifferli K. Biophysical and biochemical insights in the design of immunoassays. Biochimica et Biophysica Acta - General Subjects. 2023;1867(1):130266. DOI: 10.1016/j.bbagen.2022.130266. PMID: 36309294.
- Mirica AC, Stan D, Chelcea IC, et al. Latest Trends in Lateral Flow Immunoassay (LFIA) Detection Labels and Conjugation Process. Frontiers in Bioengineering and Biotechnology. 2022;10:922772. DOI: 10.3389/fbioe.2022.922772. PMID: 35774059.
- Cate DM, Bishop JD, Hsieh HV, et al. Antibody Screening Results for Anti-Nucleocapsid Antibodies Toward the Development of a Lateral Flow Assay to Detect SARS-CoV-2 Nucleocapsid Protein. ACS Omega. 2021;6(39):25116–25123. DOI: 10.1021/acsomega.1c01253. PMID: 34608447.